Mark Anderson; The Business Of Science

EXECUTIVE SUMMARY

EXPERIENCE

Creating value comes through innovation, teamwork, scientific expertise, and a business savvy. I bring more than 20 years of experience in the Biopharma and Pharmaceutical R&D industry.

My unique expertise includes clinical pathology, pharmaceutical R&D, pharmacology, and medicinal chemistry with a team-oriented and results-oriented management style.

My experience is in infectious disease, oncology, neurodegeneration, neurology, inflammatory disease, wound healing, antimicrobials, fungal and bacterial, cardiovascular and pulmonary injury, and blood coagulation.

I work with industry leaders, physicians, and key opinion leaders (KOL) in dermatology, urology, ophthalmology, oncology, sinusitis, otitis, ENT, onychomycosis, cardiovascular disease, pulmonary injury and chronic non-healing wounds; infections, including new mechanisms of action, drug resistance, biofilm, and virulence factors.

My experience is with new chemical and biological entities (NCE/NBE) with the goal of achieving a competitive advantage, safe & effective marketable products and a return on investment. I have worked with many multidisciplinary and multinational drug discovery and development teams. I develop and lead multi-disciplinary research teams utilizing effective processes and corporate platforms to deliver high-quality new molecular entities (NME) in a fast-paced R&D environment.

The 21st century pharmaceutical landscape is rapidly changing and my experience integrates innovation, understanding physician and patient needs, teamwork in a culturally diverse environment, and knowledge of how to drive agents and devices to the market.

EDUCATION

University of Massachusetts, Lowell, MA. - Clinical Pathology certification completed 2010.

Harvard University, Cambridge, MA. - Officer/Postdoctoral Fellow in the Department of Chemical Biology & Chemistry completed 1992.

Purdue University, West Lafayette, IN. - Doctorate (Ph.D.) Natural Products & Synthesis completed 1989.

University of Minnesota, Minneapolis, MN. - Bachelor of Science (B.S.) Chemistry, Biochemistry, Microbiology Natural Products and an undergraduate Research Thesis completed 1984.

EMPLOYMENT

Consulting Services, Biotech Pharma Solutions - Chief Scientific Officer/Scientific Director, 2009 to Present. Consulting in drugs, biologics, medical devices, management, pharmaceutical R&D, pharmacology, formulations, toxicology, international projects, posology, and translational medicine. Areas of expertise include infectious disease, inflammatory disease, oncology, neurology, antimicrobials both bacterial and fungal.

Consultant at MED360 / MNOW™ Experts - February 2012 to present. MNOW™ Experts is A LeadPhysician Resource; MED360 is A Division of WorldOne.

Consultant at NovaBay Pharmaceuticals, Inc. January 2012 to present. Infectious disease and biofilm both bacterial and fungal in ophthalmology, dermatology, urology and wound healing.

NovaBay Pharmaceuticals, Inc.: Chief Scientific Officer, October 2009 to January 2012 – Pharmaceutical CSO in infectious disease including ophthalmology/ENT, dermatology, urology, sinusitis, onychomycosis, and hospital chronic non-healing wounds (wound healing), biofilm, drug resistance, and virulence factors. Collaboration contacts Alcon (US) and Galderma (US & Fr).

Consulting Services, Biotech Pharma Solutions - President and Chief Scientific Officer/Scientific Director, 2009. Consulting in drugs, biologics, medical devices, management, pharmaceutical R&D, pharmacology, formulations, toxicology, international projects, posology, and translational & functional medicine.

Myriad Genetics & Myriad Pharmaceuticals: Vice President; Chemistry R&D, 2003 to 2009 – Oncology (Cancer), Alzheimer’s Genetics, HIV, infectious disease, inflammatory disease, blood coagulation, disease pathology, blood-brain barrier penetration, formulations, salt forms, polymorphs, selection of IND candidates, clinical development team, posology, epigenetic and novel targets.

Elitra Pharmaceuticals: Senior Director, 2002 to 2003 – Concentration in Infectious disease (bacterial and fungal), US & International collaborations and management.

Pfizer La Jolla Labs – Agouron Pharmaceuticals: Associate Director of Medicinal Chemistry, 1997 to 2002 – Neuroendocrine, Cancer (oncology), viral disease, infectious disease, medicinal chemistry, project leadership, drug design, SBDD, combinatorial lead expansion, and management.

Ligand Pharmaceuticals - Glycomed, Inc: Senior Research Scientist 1992 to 1997 - International project leadership, oncology, inflammatory disease and cell-adhesion, wound healing, mediated pathologies, pulmonary and cardiovascular injury, asthma, and drug formulations.

CONFERENCES AND PROFESSIONAL SOCIETIES

2012 Presentations: R. Bryan Miller Symposium, March 15-16 at UC Davis. Invited speaker on “Hydrogel Drug Delivery for the infectious disease; The Treatment of Impetigo”.

2011 Presentations: NeutroPhase® Product Launch at the Symposium on Advanced Wound Care (SAWC), Las Vegas, NV; October 13 – 15, 2011; Wound Healing, Infectious disease invited talk on Impetigo at the Cambridge Healthtech Institute (CHI) Conference; San Diego, CA 2011; Infectious disease invited talk on Impetigo at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011; Invited panel discussion on Corporate Collaborations & Partners at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011.

MEMBERSHIPS

Regulatory Affairs Professionals Society (RAC); Association for Molecular Pathology (AMP); American Society for Investigative Pathology (ASIP); American Society of Microbiology (ASM); American Chemical Society (ACS).

Wound Care: Society for Advanced Wound Care (SAWC), Wound Healing Society (WHS).

Medical Devices: Multidisciplinary Alliance Against Device-Related Infections (MADRI), Pre-Filled Syringes (4th PFS London).

Ophthalmology: Association for Research in Vision and Ophthalmology (ARVO), American Academy of Ophthalmology (AAO).

Dermatology, Urology & Other: Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), and Infectious Diseases Society of America (IDSA).

SELECTED CONTINUING EDUCATION COLLOQUIUMS

ARVO Clinical Trials Education Series: “Designing and Managing Clinical Trials in Eye Research.” May 1, 2010, 8:30 am – 5pm, Fort Lauderdale, FL.

UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Angiogenesis Inhibitors in the Treatment of Solid Tumors”; Lee Rosen, M.D. January 22, 2001.

UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Nonmyeloablative Stem Cell Transplantation Using Low-dose Total Body Irradiation, Cyclosporine and MMF”; Peter McSweeney, M.D. February 26, 2001.

UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Current Therapeutic Opinions in the Management of Cell Malignancies”; Michael Keating. November 6, 2000.

UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “New Endocrine Approaches for Breast Cancer: Oncology Prevention and Treatment”; C. Kent Osborne, M.D. October 23, 2000.

UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “New Approaches to Therapy of Acute Myelogenous Leukemia, blood coagulation”; Richard Stone, M.D. October 2, 2000.

UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Biology and Therapy of Advanced Prostate Cancer, Oncology”; Christopher Logothetis, M.D. June 8, 1999.

OVERVIEW OF INTELLECTUAL PROPERTY

100+ US & international issued and pending patent applications covering cancer (e.g. glioblastoma, methods for treating cancer, blood-brain barrier crossing agents, etc.); infectious disease (e.g. HIV maturation inhibitors, novel anti HIV agents, etc.); cancer agents associated with signal transduction (e.g. caspase activators and inducers of apoptosis); neuroendocrine (e.g. non-peptide GnRH agents); neurodegeneration (e.g. Alzheimer’s disease, neurology, oncology); kinases (e.g. cell cycle); viral infections; vascular disrupting agents; inflammatory diesease, autoimmune diseases; etc. The end result is a history of multiple agents in the clinic. See below.

OVERVIEW OF PUBLICATIONS

50+ publications and cited publications in infectious disease clinical studies (e.g. impetigo, viral conjunctivitis); cancer (e.g. vascular disrupting agents, novel agents, oncology); neurodegeneration (Alzhiemer’s, neurology); inflammatory disease (e.g. lung and cardiac injuries); elucidation novel mechanisms of action; bacterial biofilm; virulence factors, drug resistance; reviews (e.g. 2009 - Current Bioactive Compounds, 2003 - Annual Reports in Medicinal Chemistry, 1994 - Burger's Medicinal Chemistry Chapter 22), etc.

40+ presentations and posters at Cambridge Healthtech Institute (CHI), Anti-Infectives Summit, Society of Toxicology and American Heart Association; and posters at e.g. ARVO, ICAAC, IDSA, and ACS.